Clinical trials: Allergy; Dermatitis
Atopic Dermatitis
A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis
The objective of this study was to evaluate the safety and efficacy of multiple doses of upadacitinib monotherapy versus placebo in the treatment of adults with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT02925117
- Testing
- Upadacitinib
- Where
- 34 sites in United States, Australia and 6 more
- Volunteers
- 167 people
- Sponsor
- AbbVie
Pruritus, Atopic Dermatitis
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
- Trial name
- ATOMIK (NCT02975206)
- Testing
- Serlopitant High Dose, Serlopitant Low Dose
- Where
- 52 sites in United States
- Volunteers
- 484 people
- Sponsor
- Vyne Therapeutics Inc.
Atopic Dermatitis, Psoriasis
Evaluating Treatment Resistant Dermatitis TaroIIR
Psoriasis and atopic dermatitis are chronic inflammatory disease that account for a significant amount of patients in most dermatological practices.
- Trial name
- NCT03050294
- Testing
- Phone calls, Desoximetasone 0.25% spray
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Atopic Dermatitis
Topical Roflumilast in Adults With Atopic Dermatitis
The purpose of this study is to evaluate the effect of topical roflumilast on the reduction of atopic dermatitis lesions in adults with atopic dermatitis.
- Trial name
- NCT01856764
- Testing
- 0.5% Roflumilast Cream, Vehicle Cream
- Where
- 3 sites in Germany
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Psoriasis, Eczema
Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis
The purpose of this study is to assess the efficacy of Neuroskin Forte in relieving the symptoms of dry skin in adults with psoriasis or eczema.
- Trial name
- NCT00143819
- Testing
- Neuroskin Forte
- Volunteers
- 13 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Atopic Dermatitis
A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADVISE (NCT04162769)
- Testing
- Etrasimod 1 mg, Etrasimod 2 mg
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 140 people
- Sponsor
- Arena Pharmaceuticals
Atopic Dermatitis
Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome
To demonstrate the superiority of IMP (1% OPA-15406 ointment or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary endpoint in…
- Trial name
- NCT03908970
- Testing
- 1% OPA-15406
- Where
- Japan
- Volunteers
- 364 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis, Plaque Psoriasis
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
This study is being conducted to provide data on efficacy, safety, tolerability and PK of PF-07038124 ointment versus vehicle control in the treatment of mild to moderate AD and mild to moderate plaque psoriasis.
- Trial name
- EMPORIA (NCT04664153)
- Testing
- PF-07038124 ointment, Vehicle ointment
- Where
- 29 sites in United States, Australia and 2 more
- Volunteers
- 104 people
- Sponsor
- Pfizer
Dermatitis, Atopic, Pruritus
A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis
The goal of this clinical trial is to evaluate ASN008 in people with itch caused by eczema. The main questions it aims to answer are: What is the efficacy and safety of ASN008? What is the impact of ASN008 on itch in patients…
- Trial name
- NCT05870865
- Testing
- ASN008, ASN008 Matching Vehicle
- Where
- 27 sites in United States
- Volunteers
- 144 people
- Sponsor
- Formation Bio, Inc.
Atopic Dermatitis
Tolerance and Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis
Atopic dermatitis is one of the most frequent skin diseases. The disease is often worst during winter months when the skin is drier. Mild to moderate cases of atopic dermatitis are often controlled by a moisturizer alone.
- Trial name
- NCT00931411
- Testing
- Formulation 609580 20, Formulation 609209 (Lipikar Baume)
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Cosmetique Active International
Atopic Dermatitis
Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis
The purpose of this study is to assess the efficacy of short-term treatment with fluocinonide cream 0.1% (Vanos®) in the treatment of atopic dermatitis (AD).
- Trial name
- NCT01469767
- Testing
- Fluocinonide cream
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University
Atopic Dermatitis
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and…
- Trial name
- TRuE-AD4 (NCT06238817)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 241 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Effect of OC000459 on Moderate to Severe Atopic Dermatitis
The purpose of this study is to determine whether OC000459 is in reducing disease severity and preventing flares in people with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT02002208
- Testing
- OC000459
- Where
- United Kingdom
- Volunteers
- 142 people
- Sponsor
- Atopix Therapeutics, Ltd.
Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
The purpose of this study is to assess the efficacy and safety of twice daily ruxolitinib cream in adolescents and adults with Atopic Dermatitis (AD).
- Trial name
- NCT03745638
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 79 sites in United States, Canada and 5 more
- Volunteers
- 631 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis (AD)
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
The purpose of this 14-day, two phase clinical study is to test the tolerance of a new over-the-counter moisturizing balm on subjects with eczema.
- Trial name
- NCT02357940
- Testing
- Experimental Product
- Where
- 2 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Atopic Dermatitis
Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis
The purpose of this study is to compare the safety and efficacy profiles of Watson Laboratories, Inc.'s Pimecrolimus Cream, 1% to those of Valeant Pharmaceuticals North America LLC's Elidel® (pimecrolimus) Cream, 1%, and to…
- Trial name
- NCT02791308
- Testing
- Pimecrolimus Cream 1% (Valeant), Vehicle cream, Pimecrolimus Cream, 1%
- Where
- 53 sites in United States
- Volunteers
- 587 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Atopic Dermatitis
The Effectiveness of Montelukast on Atopic Dermatitis in Koreans
The purpose of this study is to assess the clinical effectiveness of Montelukast in children (2~6 years old) with atopic dermatitis and identify the pathophysiologic background of Montelukast on the role of modulating the atopic…
- Trial name
- NCT00903357
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Pyun BokYang
Atopic Dermatitis
Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.
This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. The trial is designed to establish a dose-response signal and investigate the efficacy and safety of delgocitinib cream in the…
- Trial name
- NCT03725722
- Testing
- Delgocitinib cream, Delgocitinib cream vehicle
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 251 people
- Sponsor
- LEO Pharma
Atopic Dermatitis, Eczema
Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
Atopic Dermatitis (AD) or eczema is a chronic relapsing inflammatory disease that affects 1-3% of the adults and up to 25% of the children in the United States.
- Trial name
- NCT01149759
- Testing
- Cyclosporine A
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rockefeller University
Allergic Contact Dermatitis
The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis
The study will investigate if Anakinra can ameliorate allergic contact dermatitis in participants with known nickel allergy
- Trial name
- NCT05498467
- Testing
- Anakinra, Sodium Chloride 9mg/ml Injection
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Herlev and Gentofte Hospital